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Purpose: Cerebral low-grade gliomas (LGG) in adults are mostly composed of astrocytomas, oligodendrogliomas, 
and mixed oligoastrocytomas. There is at present no consensus in the policy of treatment of these tumors. We 
sought to determine the efficacy of radiotherapy and the presence of a dose-response relationship for these tumors 
in two multicentric randomized trials conducted by the European Organization for Research and Treatment of 
Cancer (EORTC). The dose-response study is the subject of this article.
Methods and Materials: For the dose-response trial, 379 adult patients with cerebral LGGs were randomized 
centrally at the EORTC Data Center to receive irradiation pos tope rati vely (or postbiopsy) with either 45 Gy in 
5 weeks or 59.4 Gy in 6.6 weeks with quality-controlled radiation therapy. All known parameters with possible 
influences on prognosis were prospectively recorded. Conventional treatment techniques were recommended.
Results: With 343 (91%) eligible and evaluable patients followed up for at least 50 months with a median of 74 months, 
there is no significant difference in terms of survival (58% for the low-dose arm and 59% for the high-dose arm) or the 
progression free survival (47% and 50%) between the two arms of the trial. However, this prospective trial has revealed 
some important facets about the prognostic parameters: The T of the TNM classifications as proposed in the protocol 
appears to be one of the most important prognostic factors ip <  0.0001) on multivariate analysis. Other prognostic factors, 
most of which are known, have now been quantified and confirmed in this prospective study.
Conclusion: The EORTC trial 22844 has not revealed the presence of radiotherapeutic dose-response for patients 
with LGG for the two dose levels investigated with this conventional setup, but objective prognostic parameters 
are recognized. The tumor size or T parameter as used in this study appears to be a very important fac­
tor. Copyright © 1996 Elsevier Science Inc.
Low-grade glioma, Radiotherapeutic dose-response, T of the TNM staging classification, Prognostic factors.
Reprint requests to: Professor A. B. M. F. Karim, Radiation 
Oncology, Academic Hospital Vrije Universiteit, P.O. Box 7057, 
De Boelelaan 1117, Amsterdam, The Netherlands. E-mail: 
radiother @ azvu.nl
Acknowledgements—The authors thank Professor F. C. Stam and 
Dr. W. Kamphorst, of the Department of Pathology, Free Uni­
versity Hospital, Amsterdam; Dr. M. Kaiser, of the Depsrtment 
of Radiology, General Hospital, Luxembourg; Dr. J. H. Kralen- 
donk and Dr. M. Ros, of the Department of Radiation Oncology,
Free University Hospital, Amsterdam; Professor D. G. Gonzalez 
and Dr. M. C. C, M. Hulshof, of the Department of Radiation 
Oncology, Academic Medical Center, Amsterdam; Dr. A. C. A. 
Mak, of the Department of Radiation Oncology, Deventer Hos­
pital, The Netherlands; and Mrs. R. Bergström, of the Depart­
ment of Radiation Oncology, Free University Hospital, 
Amsterdam.
Accepted for publication 5 July 1996.
549
550 I. J. Radiation Oncology •  Biology •  Physics Volume 36, Number 3, 1996
INTRODUCTION
There is at present no consensus on the policy of treatment 
for patients with low-grade gliomas (LGG). Surgery is 
usually attempted and either biopsy or subtotal or total 
excision is undertaken. In some situations, stereotactic bi­
opsy is a possibility where eloquent areas of the brain are 
involved by the tumor.
After surgery or histopathologic verification different 
policies in general are being pursued: The wait-and-see 
policy is followed by some (1), and they initiate retreat­
ment usually by surgery followed by radiotherapy on pro­
gression of the disease. The other school (4-5, 12, 
15) treats the patients with planned immediate postoper­
ative radiotherapy. Some institutions follow no definite 
policy, and sometimes (8) postoperative radiotherapy is 
used, perhaps in difficult clinical situations. In some sit­
uations radiation therapy is being advocated even without 
biopsy (14), particularly when any surgical intervention is 
fraught with the risks of unacceptable complications.
The speculative reasons for initiating early radiation 
therapy after histopathologic typing and grading are being 
recently spelled out clearly (12).
For those believing in the efficacy of early radiation 
therapy, the optimal dose of radiotherapy is not known, 
although many retrospective publications indicate the ex­
istence of a dose-response for LGG, since the classical 
publication by Fazekas (4) revealed steep dose-response 
for LGG. Better overall survival is claimed (15) when pa­
tients with LGG are irradiated with a higher dose. The 
existence of a dose-response for irradiated glioma, how­
ever, has never been settled with a randomized controlled 
clinical trial.
The lack of consensus on the efficacy of radiotherapy 
and the question of dose-response or the optimal dose of 
radiations to be chosen for LGG has been the pivotal ques­
tion in the Radiotherapy Cooperative Group of the Euro­
pean Organization for Research and Treatment of Cancer 
(EORTC) since 1983. After prolonged deliberations, two 
randomized controlled trials, EORTC 22844 and 22845, 
were initiated in 1985 and 1986, respectively, for patients 
with LGG. The former trial deals with the question of 
existence of dose-response and is composed mostly of 
the believers in radiation therapy. Trial 22845 questions 
the efficacy of radiotherapy for LGG and is composed 
mostly of the nonbelievers in radiation therapy. It also 
tries to solve the question of early vs. late postoperative 
radiotherapy.
The EORTC trial 22844 on dose-response started ran­
domization in April 1985. It continued until September 
1991 and had accrued 379 patients when further accrual 
was stopped. The Brain Tumor Cooperative Group of the 
EORTC joined forces early in the initiation period of the 
trial.
The purpose of this article is to report the results of the 
dose-response study with a minimum follow-up of 4.6 
years, while the first group of patients was randomized
more than 10 years ago. The median follow-up is >  5 
years.
Through this prospective study a number of unan­
swered questions or controversial uncertainties apart from 
the existence of radiotherapeutic dose response were 
planned to be examined: (a) the T of TNM (8) staging 
classification, (b) the influence of the extent of surgical 
removal of the tumor, and (c) prognostic factors.
METHODS AND MATERIALS
From 10 countries, 27 institutions participated in 
selecting, randomizing, and treating 379 patients accord­
ing to EORTC protocol 22844. Informed consent was 
obtained.
PATIENTS
All adult patients (age 16-65 years) having a definite 
histopathologic diagnosis of low-grade astrocytomas (G1 
and G2)s oligodendroglioma, and mixed oligoastrocyto- 
mas of the supratentorial areas had been included for this 
trial. The histopathologic typing and grading were based 
on the diagnosis at the study hospital. A panel of neuro­
pathologists had previously defined the guidelines for typ­
ing and grading of the LGG in the protocol. These guide­
lines were based on the principles of the World Health 
Organization (WHO) classification (17) and were made 
available to the pathologist of each of the participating 
institutions. Grade 1 (pilocytic) astrocytoma, if totally ex­
cised, was excluded, while Grade 2 astrocytoma, even if 
totally excised, was included for randomization. Oligo­
dendrogliomas and mixed oligoastrocytomas were in­
cluded. The patients had to have been in reasonable to 
good general condition as indicated by performance score 
after surgery: Karnofsky index s: 60 and WHO score
2. Neurologic deficit status was also recorded and defined: 
1 = no deficit; 2 = some deficit but with adequate func­
tioning for useful work; 3 = moderate functional impair­
ment with movement difficulties, moderate dysphasia, pa­
resis, and visual or memory impairment; 4 = major 
functional impairment; and 5 = lack of conscious re­
sponse. The patients in Categories 4 and 5 were excluded 
from this trial.
Patients with pregnancy or gross hepatic, renal, or car­
diovascular diseases or malignancy other than curable skin 
cancers were excluded. However, patients thought to be 
cured of cancer at least 5 years before inclusion in the 
protocol were eligible.
Workup, stratification, and randomization
All adult patients with the histopathologic diagnosis of 
LGG had to have had preoperative and postoperative rou­
tine examinations to fulfil the selection criteria of the trial. 
Some patients had biopsy or minimum resection of the 
tumor. None had stereotactic resection of the tumor as is 
being practiced recently in some centers (13). The clinical
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data as well as preoperative CT scans were accepted as 
baseline investigations. The surgical procedures provided 
data on whether biopsy or minimal excision (<50% of the 
estimated volume of the tumor removed) or bulk removal 
(50-89%) or almost total (^90%) removal of the tumor 
had been undertaken. It was accepted after much discus­
sion that this would be a rough but prospectively noted 
estimation by the neurosurgeon. Complex volumetric 
studies with CT scans were not undertaken in light of the 
complexities of a multicentric trial and the available tech­
nology and expertise in the early 1980s. However, one 
important parameter proposed in the protocol was to col­
lect data prospectively on the T parameter of the TNM 
classification (6, 12). In view of the virtual nonexistence 
of the métastasés (N or M) and the mandatory inclusion 
of only low-grade tumors, the T parameter was given im­
portance; it was defined as early as 1983 (Table 1) based 
on the personal experience (12) of the study chairman and 
inconclusive results of a study (16) based on the UICC 
classification (6).
A maximal permissible interval of 8 weeks between the 
day of operation and initiation of radiation therapy was 
allowed. Usually this interval was <  4 weeks.
The present article is based on data from local neuro- 
pathologic and CT scan reports from the different partic­
ipating centers.
Study design
Randomization was organized centrally at the EORTC 
Data Center in Brussels with stratification for each insti­
tute. This was undertaken on histologic Grade (G1 or G2) 
for astrocytomas. All oligodendrogliomas or mixed tu­
mors were graded 2 for pragmatic stratification. Cerebral 
pilocytic astrocytoma, when totally excised, was not in­
cluded in the trial.
Randomization after surgery was between two doses of 
radiation: For one arm a low dose of 45 Gy in 25 fractions 
in 5 weeks was chosen, and for the other arm a higher 
dose of 59.4 Gy in 33 fractions in 6.6 weeks was chosen. 
In both arms 1.8 Gy as daily single fraction dose was 
mandatory.
Follow-up with routine and neurologic examinations as 
well as CT scans were advised to detect progression of
the disease. End points of the study were overall survival 
and progression-free survival (PFS). The survival was 
computed from the date of randomization to the date of 
death. The PFS was computed from the date of random­
ization to the date of progression with definite regrowth 
or recurrence of the disease. The progression-free status 
of a patient was defined when clinical and radiologic (CT 
and, later, magnetic resonance imaging) evidence of tu- 
moractivity were not noted during follow-up. Patients who 
died of causes other than cancer were censored at the date 
of death in the progression-free survival analysis.
Radiation therapy and quality control
Similar modern radiation therapy with computed do­
simetry was recommended for all participating institu­
tions. They were advised to use 4-10-M V photons, with 
build-up where necessary (for 10-MV photons). 60Co y  
apparatus was allowed when a linear accelerator was not 
available. Only 2 institutions of 27 used 60Co y  rays. Both 
of these institutions as well as some others were visited 
by the study chairman (A.B.M.F.K.) for the purpose of 
quality control. The institutional setup, surgical treatment, 
and radiotherapeutic quality of treatment, dosimetry, and 
techniques were found to be satisfactory in these institu­
tions. Most other participating centers have been visited 
by the EORTC committee for quality control.
Technique. Parallel opposing, oblique wedge fields, or 
multiple crossfiring fields were used. Multiple crossfiring 
fields were encouraged. Shrinking fields were used for the 
high-dose arm (59.4 Gy), and smaller sizes of sets of fields 
were used at 45 Gy and, whenever possible, also at 54 Gy. 
The target volume had to cover the contrast-enhanced 
areas with a margin of 2 cm, and for the nonenhanced 
tumor the presumed tumor area with the hypodense zone 
was covered with a minimum margin of 1 cm. For the 
higher-dose arm, a margin of 1 cm was allowed after 45 
Gy, and after 54 Gy a minimal margin was proposed. All 
fields should have been treated daily.
Doses were specified according to the International 
Commission on Radiological Units (7) Report No. 29.
Data collection
Forms for reporting the data on patients were developed 
for this study which had to be sent by the responsible local
Table 1. T parameter of the TNM staging classification for low-grade glioma as proposed in the protocol*
Definitions of
primary tumor (T)
Tla Greatest diameter ^ 3  cm, but confined to one side only.
Tib Greatest diameter ^ 5  cm that may be located unilaterally or smaller tumor situated relatively centrally.
T2 Greatest diameter > 5  cm, < 10  cm, but not encroaching on the ventricles or crossing the midline.
T3 Tumors of any size definitely encroaching on the ventricular system but not crossing the midline.
T4 Any massive tumor not conforming to the characteristics of T3 tumors, crossing the midline or the
tentorium.
* The classification applies only to histopathologically verified (Grades 1 and 2) low-grade cerebral glioma of the adult, particularly 
for astrocytoma, oligodendroglioma, and mixed oligoastrocytoma. T category was assessed on imaging and operative findings.
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Table 2. Clinical and pathologic data on patient population in
the two treatment groups [n (%)]
Low dose 
(n =  171)
High dose 
0n =  172)
Age (median in yr) 38 39
<30 yr 41 (12%) 37 (11%) =  (23%)
30-40  yr 57 (17%) 50 (15%) -  (32%)
4 1 -5 0  yr 39 (11%) 45 (13%) =  (24%)
> 50  yr 34 (10%) 40 (11%) = (21%)
Sex (M*.F) 105:66 91:81
Tumor location
Leftrright: central 74:86:11 78:89:5
Tumor site
Frontal: temporal 77:35 66:47
Parietal: occipital 19:4 34:0





Grade 1 (pilocytic) 15 17 =  (9%)
Grade 2 105 101 =  (60%)
Oligodendroglioma 35 38 =  (22%)
Mixed oligoastrocytoma 16 16 =  (9%)
physicians of the participating centers to the EORTC Data 
Center in Brussels. The quality of the data was reviewed 
by the data manager of the EORTC (M.P.). All forms were 
reviewed by the study chairman. Data were analyzed with 
the help of the data manager and statistician (M.V.) in 
close cooperation with the study chairman.
Statistical analysis
The survival and the progression-free survival were es­
timated by the Kaplan-Meier method (9). Comparisons 
between the two treatment arms were performed using the 
log rank test. A prognostic factor analysis included an uni­
variate and multivariate analyses. The Kaplan-Meier 
method and log rank test were used for the univariate anal­
ysis; the Cox regression model (3) was used for multi­
variate analysis.
RESULTS
The trial has accrued 379 patients from whom data on 
343 patients (91%) were found to be evaluable. The min­
imum length of follow-up is 54 months and the median is 
74 months. Altogether 36 patients were excluded owing






(n = 172) Total (%)
Minimal biopsy or <50% 73 83 156 (45%)
Bulk removal 50-89% 58 45 103 (30%)
Total or 90-100% 40 44 84 (25%)
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Table 4. Causes of death in 133 patients with median





Brain tumor 64 (48%) 59 (44%)
Cardiovascular or
pulmonary causes 2 2
Second primary 0 4*
*
Others 1 i f
* Two gastrointestinal, 1 lung, and 1 metastatic carcinoma of 
unknown primary.
1 One suicide and 1 cause of death unknown.
to ineligibility. The reasons for ineligibility were incom­
plete data in 16 patients, wrong localization of the tumor 
and/or incorrect histopathology in 11 patients, low per­
formance score in 4 patients, and prior treatment or delay 
in initiating radiation therapy in 5 patients. The ineligible 
patients were equally distributed in the two arms of the 
trial. The characteristics of the patients and the tumor in 
both arms of the trial are listed in Table 2. The estimated 
amount of the tumor removed by the surgical procedure 
is listed in Table 3. During this period, 149 patients de­
veloped progression of the brain tumor: 79 in the low- 
dose arm and 70 in the high-dose arm. Some died of the 
tumor or of other causes. The causes of death in 133 pa­
tients are detailed in Table 4.
Figure la  and b shows the overall survival and propor­
tion of PFS for both arms of the trial. It appears that neither 
the survival nor the PFS revealed significant differences 
between the two groups of patients treated with higher or 
lower doses. The number of survivors with PFS at 5 years 
is 47% for the patients treated with the lower dose and 
50% for the other group treated with a higher dose. How­
ever, the number of patients with a minimum of 5 years 
follow-up is rather small: 37 and 35, respectively.
Prognostic values on survival and PFS
In analyzing prognostic factors, age alone was consid­
ered to be a discrete variable in the univariate analysis, 
and for multivariate analysis all cofactors such as T clas­
sification, performance, or neurologic deficit status, age, 
and so forth were entered as continuous variables. Table
5 shows the univariate and multivariate analyses on prog­
nostic factors for both survivors and progression-free sur­
vivors. Age had a significant prognostic influence (p <
0.04) on survival but not on PFS (p =  0.054). Sex was 
not a prognostic factor for LGG (p >  0.66) in this study. 
The site of the tumor had a significant prognostic influence 
for survival only on univariate analysis. The histopatho­
logic type had a significantly worse prognostic influence 
on survival for astrocytoma Grade 2 tumors than for any 
other histologic types or grading in this study. The worse 
influence was much higher for PFS on multivariate anal­
ysis (p — 0.0001). Patients with Grade 1 pilocytic astro-
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Fig. 1. (a) Survival and (b) progression-free survival (PFS) of patients treated with a low dose (45 Gy) and high 
dose (59.4 Gy).
cytoma had better survival but their number was small 
(32). In this study the neurologic deficit status appears 
to be a better predictor than the WHO performance 
status.
In view of known improved results with surgical re­
moval of the tumor (2), further analysis was undertaken 
with the parameter being the amount of tumor removed 
by surgery. Three subgroups were analyzed as detailed in 
Table 3.
While dose-response was not found to be present in 
these different subgroups of patients with different amount 
of tumor rests after surgery, the survival and PFS for each 
of these three subgroups revealed significant differences 
as shown in Fig. 2a and b and Table 5.
The T parameter of the TNM staging classification as 
proposed in the protocol (Table 1) was analyzed for 300 
patients for whom the data were available. The T param­
eters as proposed in this study are significantly discrimi­
nant (Figs. 3a and b and Table 5) for prognosis for overall 
survival (p <  0.0001) as well as PFS (p <  0.0001). The 
log rank test for trend was used for comparison of all 
ordered categorial data including the T classification.
Complications
Acute minor complications of short duration were 
noted in both arms of the trial as are usually seen during 
and after radiation (e.g., skin reactions, vomiting, head­
ache, otitis). These were not significantly higher in the
Table 5. Prognostic factors: EORTC 22844
Survival
Overall Progression free
Univariate Multivariate Univariate Multivariate
Age * t
T classification $ * $. f.
Site of the tumor t
performance status t t *
neurologic status $ $ *
Surgery (amount of tumor removed) t * $ *
Histologic type (astro., oligo, or mixed types) * * $
* p  <  0.05. 
< 0.01. 
*p  <  0.001.
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high-dose arm. However, radiotherapy had to be inter- 
upted for more than 1 week in 13 patients treated with a 
low dose and in 26 patients treated with a high dose. In 
the latter group treatment was discontinued for nine pa­
tients. Long-term sequelae, as far as was retrievable from 
follow-up CT scans, were rare, perhaps owing to the low 
daily doses used in this protocol. Virtually no definite 
necrosis of brain has been reported so far. The sequelae 
and the quality of life do not appear to be different in the 
two arms but will be reported separately later in another 
report.
DISCUSSION
The EORTC study 22844 with a large number of pa­
tients has revealed some aspects on LOG previously un­
known from a prospective multicentric study, but the 
study denies the presence of a dose—response in the 
studied dose range. This may change with a longer fol- 
low-up. New developments such as newer imaging 
methods with volumetric considerations, computer-as­
sisted stereotactic resection of tumors (13), three-di­
mensional conformal radiotherapeutic treatment tech­
niques, as well as other sophisticated developments 
(e.g., cell kinetic parameters) are not yet universally 
available. These are the new frontiers for advances 
(11) in the treatment of LGG as well as other tumors or 
lesions of the brain. Future dose—response studies 
should incorporate all of these and other developments 
with probably much higher doses. For the present, in 
the many institutions not participating in trials on LGG,
patients may be spared from the inconveniences of more 
treatment sessions if they are treated with the present 
conventional techniques. In this way valuable mega­
voltage space may be spared.
The T parameter as was defined in the protocol ap­
pears to be a good prognostic discriminator. While the 
myth of heterogeneity of the LGG should be further 
studied, the neurooncologists may start to use the T of 
the TNM staging system to separate the apples from the 
oranges or the pears in all prospective studies from now 
on. It is perhaps possible to modify and simplify further 
definitions of the T parameter. It is important to realize 
that the T parameter as defined in this study differs 
slightly from that of the UICC/AJC classification (16). 
The important deviation proposed (12) for staging 
LGGs is the size of tumor, and we are now looking for 
the clinical validity of staging LGGs only on size. This 
will be soon reported.
The influence of the age of patients on overall sur­
vival in many retrospective studies has been recognized 
and is also confirmed in this prospective study. How­
ever, the influence of age on the PFS was not signifi­
cant in this study. The parameters of neurologic and 
performance status showed prognostic influence on sur­
vival as well as PFS, but the influence of neurologic 
status appears to be more than that of the performance 
status.
It is noted that LGGs are slow-growing tumors, and 
the survival may be observed to be different from the 
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Fig. 2. (a) Survival and (b) progression-free survival (PFS) of patients whose LGGs were removed minimally 
(<50%), in bulk (50-89% ) or almost totally (90-100% ).
Randomized trial on LGG •  A. B. M. F. K a rim  et al. 555
SURVIVAL PROGRESSION FREE SURVIVAL
%100
Log - rank p< 0.001 (trend)
60
40
















Fig. 3. (a) Survival and (b) progression-free survival o f patients according to the T parameter of the TNM staging 
classification as proposed in the protocol.
CONCLUSION
There is no evidence of a dose-response for the 
LGGs for the two doses in a conventional setup as stud­
ied in this protocol. It is, however, rewarding to invest 
in the efforts of various participating centers for such a 
relatively rare tumor. The responsible neurooncologists, 
including the neuropathologists and neuroradiologists, 
have worked together to the success of the trial with
answers to some controversial issues including the 
prognostic factors from a prospective study. Of these 
factors, the proposed T staging classification demon­
strated a very significant prognostic value both for pro- 
gresion-free and overall survival in a multivariate anal­
ysis. The important question of efficacy of radiotherapy 
must now be awaited from the results of the other 4 ‘non­
believer” EORTC trial 22845.
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